Chengfei Liu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 37

Top Topics

Radical Prostatectomy

Prostate Cancer

Top Venues

Research square

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Shaoqiang Guo, Miaomiao Miao, Yufeng Wu, Dongyue Pan, Qinyan Wu, Zhanfang Kang, Jianwen Zeng, Guoping Zhong, Chengfei Liu, Jun-Jian Wang
DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer. Oncogene 43 (19) (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Shaoqiang Guo, Miaomiao Miao, Yufeng Wu, Dongyue Pan, Qinyan Wu, Zhanfang Kang, Jianwen Zeng, Guoping Zhong, Chengfei Liu, Jun-Jian Wang
DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer. Oncogene 43 (19) (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Pengfei Xu, Joy C Yang, Bo Chen, Shu Ning, Xiong Zhang, Leyi Wang, Christopher Nip, Yuqiu Shen, Oleta T Johnson, Gabriela Grigorean, Brett S Phinney, Liangren Liu, Qiang Wei, Eva Corey, Clifford G Tepper, Hong-Wu Chen, Christopher P Evans, Marc A Dall'Era, Allen C Gao, Jason E Gestwicki, Chengfei Liu
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nature communications 15 (1) (2024)
Shu Ning, Cameron M Armstrong, Enming Xing, Amy R Leslie, Richard Y Gao, Masuda Sharifi, Zachary A Schaaf, Wei Lou, Xiangrui Han, Desiree H Xu, Rui Yang, Jeffrey Cheng, Shabber Mohammed, Nicholas Mitsiades, Chengfei Liu, Alan P Lombard, Chun-Yi Wu, Xiaolin Cheng, Pui-Kai Li, Allen C Gao
LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer. Cancer research (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Shaoqiang Guo, Miaomiao Miao, Yufeng Wu, Dongyue Pan, Qinyan Wu, Zhanfang Kang, Jianwen Zeng, Guoping Zhong, Chengfei Liu, Jun-Jian Wang
DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer. Oncogene (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene (2024)
Pengfei Xu, Joy C Yang, Bo Chen, Shu Ning, Xiong Zhang, Leyi Wang, Christopher Nip, Yuqiu Shen, Oleta T Johnson, Gabriela Grigorean, Brett S Phinney, Liangren Liu, Qiang Wei, Eva Corey, Clifford G Tepper, Hong-Wu Chen, Christopher P Evans, Marc A Dall'Era, Allen C Gao, Jason E Gestwicki, Chengfei Liu
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nature communications 15 (1) (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene (2024)
Pengfei Xu, Joy C Yang, Bo Chen, Shu Ning, Xiong Zhang, Leyi Wang, Christopher Nip, Yuqiu Shen, Oleta T Johnson, Gabriela Grigorean, Brett S Phinney, Liangren Liu, Qiang Wei, Eva Corey, Clifford G Tepper, Hong-Wu Chen, Christopher P Evans, Marc A Dall'Era, Allen C Gao, Jason E Gestwicki, Chengfei Liu
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nature communications 15 (1) (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene (2023)
Pengfei Xu, Joy C Yang, Bo Chen, Christopher Nip, Jonathan E Van Dyke, Xiong Zhang, Hong-Wu Chen, Christopher P Evans, William J Murphy, Chengfei Liu
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. Journal for immunotherapy of cancer 11 (5) (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene 42 (9) (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene 42 (9) (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene 42 (9) (2023)
Christopher Nip, Leyi Wang, Chengfei Liu
CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy. Biomedicines 11 (12) (2023)
Christopher Nip, Leyi Wang, Chengfei Liu
CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy. Biomedicines 11 (12) (2023)
Christopher Nip, Leyi Wang, Chengfei Liu
CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy. Biomedicines 11 (12) (2023)
Christopher Nip, Leyi Wang, Chengfei Liu
CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy. Biomedicines 11 (12) (2023)
Pengfei Xu, Joy C Yang, Bo Chen, Christopher Nip, Jonathan E Van Dyke, Xiong Zhang, Hong-Wu Chen, Christopher P Evans, William J Murphy, Chengfei Liu
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. Journal for immunotherapy of cancer 11 (5) (2023)
Christopher Nip, Leyi Wang, Chengfei Liu
CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy. Biomedicines 11 (12) (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene 42 (9) (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene 42 (9) (2023)
Zachary A Schaaf, Shu Ning, Amy R Leslie, Masuda Sharifi, Xianrui Han, Cameron Armstrong, Wei Lou, Alan P Lombard, Chengfei Liu, Allen C Gao
Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer. Cancers 15 (21) (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene (2023)
Shu Ning, Chengfei Liu, Wei Lou, Joy C Yang, Alan P Lombard, Leandro S D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R Leslie, Masuda Sharifi, Christopher P Evans, Allen C Gao
Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Molecular cancer therapeutics 21 (10) (2022)